Endo International is selling its men’s health and prostate urology businesses to Boston Scientific Corp. for $1.6 billion, as it attempts to refocus its efforts on more lucrative parts of its portfolio and regain revenue after a rocky 2014.
As part of the deal, Boston Scientific, which enjoyed a nice boost in morning trading Monday on the news, will wrap the new unit into its own urology and women’s health department.
|Searching for more deal information? Current Partnering offers the following options:
- CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
- Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities
- CP Knowledge Centre | Login | Find out more | Provides you with an all-in-one intelligence package that allows you to simultaneously access our CP reports, CP Insight and Current Agreements deal and alliances database, at the same time
It also will shell out a potential additional $50 million milestone based on 2016 sales with the deal slated to close in the third quarter of 2015.
For further deal information visit Current Agreements (subscription required)
Scorecard: Top partnering deals by value in 2015
View: Top pharmaceutical companies
View: Top biotech companies
Reports: Browse our extensive deal making report portfolio